Combined treatment with olmesartan [olmesartan medoxomil] and a calcium channel blocker [azelnidipine] versus olmesartan and diuretics [hydrochlorothiazide]: a randomized efficacy study (J-CORE)
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Azelnidipine; Hydrochlorothiazide; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms J-CORE
- 01 Mar 2011 Results published in Atherosclerosis.
- 22 Oct 2009 Results have been published in Hypertension.
- 20 Nov 2008 Biomarkers information updated